A pregnancy vaccine against respiratory syncytial virus (RSV) reduces hospitalizations in infants by 80 percent, according to a new study. The vaccine, administered to pregnant women, provides newborns with passive immunity during their most vulnerable months.
RSV causes severe chest infections in babies and ranks among the leading reasons for infant hospital admissions. The virus typically strikes hardest in children under six months old, before their immune systems mature. The study confirms the vaccine delivers robust protection during this critical window.
The finding represents a major breakthrough in infant health. Previously, no vaccine existed for pregnant women to protect newborns from RSV. Treatment options for infected babies remained limited to supportive care.
Researchers measured hospitalization rates among vaccinated mothers' infants against unvaccinated control groups. The 80 percent reduction in hospitalizations translates to thousands of preventable admissions annually in countries with widespread adoption.
The vaccine works by triggering the pregnant woman's immune response, which passes protective antibodies to the developing fetus through the placenta. Those antibodies persist in newborns for several months, providing passive immunity when RSV poses the greatest risk.
Health authorities now face decisions on vaccination recommendations and rollout timelines. The study strengthens the case for adding RSV vaccination to standard pregnancy protocols, potentially reshaping infant respiratory care.